A striking disparity in blood pressure control emerges when stratified by MTHFR genotype: only 37% of untreated C677T TT carriers achieved target blood pressure while on standard antihypertensive medications, compared to 64% of CC carriers. This treatment-resistant gap suggests a mechanistic vulnerability specific to TT carriers.
Clinical trial evidence from Ulster University indicates that riboflavin supplementation at 1.6 mg daily can close this disparity, pointing toward a genotype-directed intervention for otherwise refractory hypertension. This precision medicine approach could reshape management strategies for a subset of hypertensive patients. However, the findings require validation through independent research groups before widespread clinical adoption. Read the full article on GMJ Newsroom.
Was this article helpful?
